106 related articles for article (PubMed ID: 21728789)
1. Closure of persistent foramen ovale with the BioSTAR biodegradable PFO closure device: feasibility and long-term outcome.
Karagianni A; Abrahamsson P; Furenäs E; Eriksson P; Dellborg M
Scand Cardiovasc J; 2011 Oct; 45(5):267-72. PubMed ID: 21728789
[TBL] [Abstract][Full Text] [Related]
2. Percutaneous closure of patent foramen ovale with a bioabsorbable occluder device: single-centre experience.
Ussia GP; Cammalleri V; Mulè M; Scarabelli M; Barbanti M; Scardaci F; Mangiafico S; Immè S; Capodanno D; Tamburino C
Catheter Cardiovasc Interv; 2009 Oct; 74(4):607-14. PubMed ID: 19360875
[TBL] [Abstract][Full Text] [Related]
3. The BioSTAR(r) device versus the CardioSEAL(r) device in patent foramen ovale closure: comparison of mid-term efficacy and safety.
Van den Branden BJ; Luermans JG; Post MC; Plokker HW; Ten Berg JM; Suttorp MJ
EuroIntervention; 2010 Sep; 6(4):498-504. PubMed ID: 20884438
[TBL] [Abstract][Full Text] [Related]
4. Long-term transesophageal echocardiography after patent foramen ovale closure by BioSTAR and Amplatzer patent foramen ovale occluders.
Suligoj NC; Rojko M; Suligoj B; Zorc M; Kar S; Noc M
Catheter Cardiovasc Interv; 2020 Feb; 95(3):349-354. PubMed ID: 31131978
[TBL] [Abstract][Full Text] [Related]
5. New onset atrial fibrillation after patent foramen ovale closure.
Staubach S; Steinberg DH; Zimmermann W; Wawra N; Wilson N; Wunderlich N; Sievert H
Catheter Cardiovasc Interv; 2009 Nov; 74(6):889-95. PubMed ID: 19626689
[TBL] [Abstract][Full Text] [Related]
6. Patent foramen ovale closure with the Intrasept occluder: Complete 6-56 months follow-up of 247 patients after presumed paradoxical embolism.
Spies C; Timmermanns I; Reissmann U; van Essen J; Schräder R
Catheter Cardiovasc Interv; 2008 Feb; 71(3):390-5. PubMed ID: 18288745
[TBL] [Abstract][Full Text] [Related]
7. Percutaneous transcatheter closure of patent foramen ovale with the Amplatzer Cribriform septal occluder.
Silvestry FE; Naseer N; Wiegers SE; Hirshfeld JW; Herrmann HC
Catheter Cardiovasc Interv; 2008 Feb; 71(3):383-7. PubMed ID: 18288733
[TBL] [Abstract][Full Text] [Related]
8. Single center experience: Implantation failures, early, and late complications after implantation of a partially biodegradable ASD/PFO-device (BioStar®).
Happel CM; Laser KT; Sigler M; Kececioglu D; Sandica E; Haas NA
Catheter Cardiovasc Interv; 2015 May; 85(6):990-7. PubMed ID: 25511020
[TBL] [Abstract][Full Text] [Related]
9. Outcome after percutaneous closure of a patent foramen ovale using the Intrasept device: a multi-centre study.
Luermans JG; Post MC; Schräder R; Sluysmans T; Vydt T; Vermeersch P; Chessa M; Onorato E; Goy JJ; Budts WI
Catheter Cardiovasc Interv; 2008 May; 71(6):822-8. PubMed ID: 18324695
[TBL] [Abstract][Full Text] [Related]
10. Sustained long-term benefit of patent foramen ovale closure on migraine.
Trabattoni D; Fabbiocchi F; Montorsi P; Galli S; Teruzzi G; Grancini L; Gatto P; Bartorelli AL
Catheter Cardiovasc Interv; 2011 Mar; 77(4):570-4. PubMed ID: 21351231
[TBL] [Abstract][Full Text] [Related]
11. Electrocardiographic changes and arrhythmias following percutaneous atrial septal defect and patent foramen ovale device closure.
Johnson JN; Marquardt ML; Ackerman MJ; Asirvatham SJ; Reeder GS; Cabalka AK; Cetta F; Hagler DJ
Catheter Cardiovasc Interv; 2011 Aug; 78(2):254-61. PubMed ID: 21563292
[TBL] [Abstract][Full Text] [Related]
12. Recurrent cerebrovascular events in patients after percutaneous closure of patent foramen ovale.
Karagianni A; Mandalenakis Z; Dellborg M; Mirzada N; Johansson MC; Eriksson P
J Stroke Cerebrovasc Dis; 2020 Aug; 29(8):104860. PubMed ID: 32430239
[TBL] [Abstract][Full Text] [Related]
13. Patent foramen ovale--assessment and treatment.
Irwin B; Ray S
Cardiovasc Ther; 2012 Jun; 30(3):e128-35. PubMed ID: 21883994
[TBL] [Abstract][Full Text] [Related]
14. Percutaneous atrial shunt closure using the novel Occlutech Figulla device: 6-month efficacy and safety.
Van Den Branden BJ; Post MC; Plokker HW; Ten Berg JM; Suttorp MJ
J Interv Cardiol; 2011 Jun; 24(3):264-70. PubMed ID: 21198853
[TBL] [Abstract][Full Text] [Related]
15. Transcatheter closure versus medical therapy of patent foramen ovale and cryptogenic stroke.
Thanopoulos BV; Dardas PD; Karanasios E; Mezilis N
Catheter Cardiovasc Interv; 2006 Nov; 68(5):741-6. PubMed ID: 17039525
[TBL] [Abstract][Full Text] [Related]
16. Long-term outcome of transcatheter patent foramen ovale closure in patients with paradoxical embolism.
Cifarelli A; Musto C; Parma A; Pandolfi C; Pucci E; Fiorilli R; De Felice F; Nazzaro MS; Violini R
Int J Cardiol; 2010 Jun; 141(3):304-10. PubMed ID: 19178959
[TBL] [Abstract][Full Text] [Related]
17. Interventional closure with Amplatzer PFO occluder of patent foramen ovale in patients with paradoxical cerebral embolism.
Chatterjee T; Petzsch M; Ince H; Rehders TC; Körber T; Weber F; Schneider H; Auf der Maur C; Nienaber CA
J Interv Cardiol; 2005 Jun; 18(3):173-9. PubMed ID: 15966921
[TBL] [Abstract][Full Text] [Related]
18. Causes of recurrent focal neurologic events after transcatheter closure of patent foramen ovale with the CardioSEAL septal occluder.
Kutty S; Brown K; Asnes JD; Rhodes JF; Latson LA
Am J Cardiol; 2008 May; 101(10):1487-92. PubMed ID: 18471463
[TBL] [Abstract][Full Text] [Related]
19. Patent foramen ovale closure using a bioabsorbable closure device: safety and efficacy at 6-month follow-up.
Van den Branden BJ; Post MC; Plokker HW; ten Berg JM; Suttorp MJ
JACC Cardiovasc Interv; 2010 Sep; 3(9):968-73. PubMed ID: 20850098
[TBL] [Abstract][Full Text] [Related]
20. Early experience with a simplified technique for transcatheter closure of the patent foramen ovale.
Kutty S; Nykanen DG; Zahn EM
Heart Lung Circ; 2009 Dec; 18(6):384-7. PubMed ID: 19783211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
